Malignant Syringoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Malignant Syringoma

MalaCards integrated aliases for Malignant Syringoma:

Name: Malignant Syringoma ¹¹ ¹⁴

Microcystic Adnexal Carcinoma ¹¹ ¹⁹

Microcystic Adnexal Carcinoma of Skin ¹¹

Syringomatous Carcinoma ¹¹

Eccrine Epithelioma ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases Eye diseases Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:5569

UMLS ⁷¹ C0346027

Sources

Summaries for Malignant Syringoma

GARD: ¹⁹ Microcystic adnexal carcinoma is a rare tumor of the skin that most often develops in the head and neck region, particularly in the middle of the face, though it may occur in the skin of other parts of the body as well. This tumor is often first noticed as a bump or yellowish spot in the skin. Though Microcystic adnexal carcinomas frequently grow into and disturb nearby tissues and is therefore considered an invasive cancer, this type of tumor rarely spreads to more distant parts of the body (metastasizes).

MalaCards based summary: Malignant Syringoma, also known as microcystic adnexal carcinoma, is related to infiltrative basal cell carcinoma and external ear carcinoma. An important gene associated with Malignant Syringoma is PHLDA1 (Pleckstrin Homology Like Domain Family A Member 1), and among its related pathways/superpathways are COPI-independent Golgi-to-ER retrograde traffic and Cytoskeletal Signaling. The drugs Nivolumab and Talimogene laherparepvec have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and bone marrow, and related phenotype is digestive/alimentary.

Sources

Related Diseases for Malignant Syringoma

Diseases in the Syringoma family:

Syringomas, Multiple

Malignant Syringoma

Diseases related to Malignant Syringoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 440)

#	Related Disease	Score	Top Affiliating Genes
1	infiltrative basal cell carcinoma	30.6	KRT17 KRT15
2	external ear carcinoma	30.2	KRT7 KRT5 CEACAM5
3	sebaceous adenocarcinoma	30.2	PIP KRT7 KRT5
4	muir-torre syndrome	30.1	PTGER4 KRT7 KRT5
5	teratoma	30.1	KRT7 KRT20 CEACAM5
6	meibomian cyst	30.1	PIP KRT7 KRT20
7	papilloma	30.0	KRT7 KRT5 KRT20
8	skin benign neoplasm	30.0	PIP KRT7 KRT5 KRT20 CD34
9	malignant acrospiroma	30.0	PIP PHLDA1 KRT7 KRT5 CEACAM5
10	eyelid carcinoma	29.9	PIP KRT7 KRT20
11	morpheaform basal cell carcinoma	29.9	PHLDA1 KRT20 KRT17 KRT15 CD34
12	sweat gland benign neoplasm	29.8	PIP KRT7 KRT5 CEACAM5 CD34
13	syringoma	29.8	PIP KRT7 KRT19 CEACAM5
14	apocrine sweat gland neoplasm	29.8	PIP KRT7 KRT5 KRT15 CEACAM5
15	adenoid cystic carcinoma	29.7	KRT7 KRT20 KRT19
16	cystic teratoma	29.7	KRT7 KRT20 CEACAM5 CD34
17	keratoacanthoma	29.6	KRT19 KRT17 KRT15
18	polycystic liver disease 1 with or without kidney cysts	29.6	KRT7 KRT20 KRT17 CEACAM5
19	breast ductal carcinoma	29.6	PIP KRT7 KRT5 KRT19
20	syringocystadenoma papilliferum	29.6	PIP PHLDA1 KRT7 KRT5 KRT15 CEACAM5
21	benign teratoma	29.4	KRT7 KRT5 KRT20 CEACAM5 CD34
22	basal cell carcinoma	28.8	PTGER4 PIP KRT7 KRT5 KRT20 KRT19
23	clear cell basal cell carcinoma	28.5	PHLDA1 KRT7 KRT5 KRT20 KRT19 KRT17
24	sweat gland cancer	28.3	PIP PHLDA1 KRT7 KRT5 KRT20 KRT19
25	basal cell carcinoma 1	10.7
26	rare tumor	10.5
27	macs syndrome	10.4
28	fanconi anemia, complementation group e	10.4
29	squamous cell carcinoma	10.4
30	skin squamous cell carcinoma	10.4
31	pilar sheath acanthoma	10.3	PHLDA1 KRT15
32	epidermal appendage tumor	10.3	PHLDA1 KRT15
33	acanthoma	10.3	PHLDA1 KRT5
34	atrophoderma vermiculata	10.3
35	skin carcinoma	10.3
36	sebaceous breast carcinoma	10.3	PIP CEACAM5
37	fox-fordyce disease	10.3	PIP CEACAM5
38	peritoneal serous papillary adenocarcinoma	10.3	PTGER4 PIP
39	villous adenoma	10.3	KRT7 CEACAM5
40	mucoepidermoid esophageal carcinoma	10.3	KRT5 CEACAM5
41	papillary thymic adenocarcinoma	10.3	PTGER4 CEACAM5
42	ovarian cystadenoma	10.3	KRT7 CEACAM5
43	peritoneal serous adenocarcinoma	10.3	PTGER4 PIP
44	leukoplakia of penis	10.3	KRT7 CEACAM5
45	clear cell acanthoma	10.2	KRT5 CEACAM5
46	pancreatic foamy gland adenocarcinoma	10.2	KRT7 CEACAM5
47	anal canal paget's disease	10.2	PIP KRT7
48	anal gland adenocarcinoma	10.2	PIP KRT7
49	anus adenocarcinoma	10.2	PIP KRT7
50	oncocytic breast carcinoma	10.2	PIP KRT7

Graphical network of the top 20 diseases related to Malignant Syringoma:

Sources

Symptoms & Phenotypes for Malignant Syringoma

MGI Mouse Phenotypes related to Malignant Syringoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.1	CEACAM5 KRT15 KRT17 KRT19 KRT5 PIP

Sources

Drugs & Therapeutics for Malignant Syringoma

Drugs for Malignant Syringoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Nivolumab

Approved

Phase 2

946414-94-4

2

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 2

1187560-31-1

3

Immune Checkpoint Inhibitors

Phase 2

4

Antineoplastic Agents, Immunological

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	Recruiting	NCT02978625	Phase 2

Search NIH Clinical Center for Malignant Syringoma

Sources

Genetic Tests for Malignant Syringoma

Sources

Anatomical Context for Malignant Syringoma

Organs/tissues related to Malignant Syringoma:

MalaCards : Skin, Lymph Node, Bone Marrow, Breast, Salivary Gland, Smooth Muscle, Tongue

Sources

Publications for Malignant Syringoma

Articles related to Malignant Syringoma:

(show top 50) (show all 328)

#	Title	Authors	PMID	Year
1	Epidemiological and Clinical Features of 49 Hispanic Patients With Microcystic Adnexal Carcinoma. ⁶²	Robles-Tenorio A...Tarango Martinez VM	36368580	2022
2	Margin Size for Unique Skin Tumors Treated With Mohs Micrographic Surgery: A Survey of Practice Patterns. ⁶²	Walocko FM...Nijhawan RI	36446119	2022
3	Microcystic adnexal carcinoma misdiagnosed as a "recurrent epidermal cyst": A case report. ⁶²	Yang SX...Li FQ	36158483	2022
4	Epidemiological and Clinical Features of 49 Hispanic Patients With Microcystic Adnexal Carcinoma. ⁶²	Robles-Tenorio A...Tarango Martinez VM	35753362	2022
5	A review of Mohs micrographic surgery for skin cancer. Part 1: Melanoma and rare skin cancers. ⁶²	Charalambides M...Wernham A	34939669	2022
6	Four calcium signaling pathway-related genes were upregulated in microcystic adnexal carcinoma: transcriptome analysis and immunohistochemical validation. ⁶²	Yu S...Sun H	35509066	2022
7	Sclerosing Microcystic Adenocarcinoma Arising from the Tongue: A Case Report and Literature Review. ⁶²	Lee YY...Chen CC	35626443	2022
8	Does Immunohistochemistry Add to Morphology in Differentiating Trichoepithelioma, Desmoplastic Trichoepithelioma, Morpheaform Basal Cell Carcinoma, and Microcystic Adnexal Carcinoma? ⁶²	Mohanty SK...Frishberg DP	35384877	2022
9	Impact of expert pathology review in skin adnexal carcinoma diagnosis: Analysis of 2573 patients from the French CARADERM network. ⁶²	Battistella M...CARADERM network	35090811	2022
10	Microcystic adnexal carcinoma of the scalp treated with surgical resection along with chemoradiation: A case report and review of the literature. ⁶²	Al-Wassia RK...Al-Qathmi MS	34867014	2021
11	Microcystic Adnexal Adenoma: The Benign Counterpart of Microcystic Adnexal Carcinoma. ⁶²	Torre-Castro J...Requena L	33859082	2021
12	Desmoplastic Trichoepithelioma With Pseudocarcinomatous Hyperplasia: A Folliculosebaceous Neoplasm in Young Persons. ⁶²	Wang MZ...LeBoit PE	33899770	2021
13	Emerging therapies for rare cutaneous cancers: A systematic review. ⁶²	Garcia A...Patel V	34418780	2021
14	Primary Alopecia Neoplastica: A Novel Case Report and Literature Review. ⁶²	Flanagan KE...Senna MM	34901185	2021
15	Matrix Metalloproteinase 28-Bearing Microcystic Adnexal Carcinoma on the Back. ⁶²	Chiba H...Fujimura T	35082639	2021
16	Expression of Hedgehog signalling molecules in microcystic adnexal carcinoma. ⁶²	Gambichler T...Lang K	33714217	2021
17	Sweat duct proliferation associated with aggregation of elastic tissue and atrophodermia vermiculata: a simulator of microcystic adnexal carcinoma - a family with MALTA-syndrome. ⁶²	Mentzel J...Ziemer M	34015181	2021
18	Microcystic Adnexal Carcinoma with Xanthomatous Reaction. ⁶²	Fujii K...Kanekura T	33734422	2021
19	Microcystic adnexal carcinoma of the glabella in a liver transplant recipient. ⁶²	Stamey CR...Book SE	33869702	2021
20	Transposition flap plastic to cover an extensive defect of the upper lip region after resection of a microcystic adnexal carcinoma. ⁶²	Silber T...Kofler L	32989922	2021
21	Dermoscopic characteristics of microcystic adnexal carcinoma, desmoplastic trichoepithelioma, and morpheaform basal cell carcinoma. ⁶²	Costello CM...Mangold AR	32686120	2021
22	Local Recurrence Rates of Skin Tumors After Resection With Complete Circumferential Peripheral and Deep Margin Assessment-Identification of High-Risk Entities. ⁶²	Kofler L...Kofler K	33565775	2021
23	Microcystic adnexal carcinoma of the head and neck: Characteristics, treatment, and survival statistics. ⁶²	Behbahani S...Schwartz RA	33210380	2021
24	MOHS micrographic surgery for head and neck nonmelanoma skin cancer: An approach for ENT surgeons. ⁶²	Castanheira A...Mota A	33301226	2021
25	Facial microcystic adnexal carcinoma - treatment with a "jigsaw puzzle" advancement flap and immediate esthetic reconstruction: A case report. ⁶²	Xiao YD...Zeng A	33553398	2021
26	Microcystic adnexal carcinoma with germinative follicular differentiation. ⁶²	Moya-Martinez C...Requena L	32895957	2021
27	Epidemiology and Survival of Microcystic Adnexal Carcinoma by Sex in the United States. ⁶²	Amon G...Maher IA	31567608	2021
28	Mohs Surgery Outside Usual Indications: A Review. ⁶²	Rodriguez-Jimenez P...Delgado Jimenez Y	33834992	2020
29	Sequencing of Sclerosing Microcystic Adenocarcinoma Identifies Mutational Burden and Somatic Variants Associated With Tumorigenesis. ⁶²	Jiang R...Judson BL	33109575	2020
30	Periocular skin cancer: Diagnosis and management. ⁶²	Moran JM...Phelps PO	32600650	2020
31	Multifocal Recurrent Microcystic Adnexal Carcinoma. ⁶²	Teixeira JC...Goodman J	32398617	2020
32	Morphologically high-grade microcystic adnexal carcinoma: a report of two cases. ⁶²	Brenn T...Calonje E	32359178	2020
33	Determinants of Microcystic Adnexal Carcinoma Management and Outcomes in British Columbia. ⁶²	Burleigh A...Crawford RI	32584171	2020
34	Microcystic adnexal carcinoma. ⁶²	Kura MM...Bijwe S	31347515	2020
35	Desmoplastic Trichoepithelioma: Histopathologic and Immunohistochemical Criteria for Differentiation of a Rare Benign Hair Follicle Tumor From Other Cutaneous Adnexal Tumors. ⁶²	Rahman J...Sonawane S	32923292	2020
36	Collision tumor of microcystic adnexal carcinoma and squamous cell carcinoma discovered on Mohs sections. ⁶²	Ken KM...Nijhawan RI	32490104	2020
37	Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. ⁶²	Chan MP...Harms PW	31857679	2020
38	Microcystic adnexal carcinoma of the skin in atypical site (pubic region): clinical and dermatoscopic features. ⁶²	Astorino S...Pasquini P	30249079	2020
39	Mohs micrographic surgery: a treatment method for many non-melanocytic skin cancers. ⁶²	Dokic Y...Orengo I	32621679	2020
40	State of the art of Mohs surgery for rare cutaneous tumors in the Spanish Registry of Mohs Surgery (REGESMOHS). ⁶²	Rodriguez-Jimenez P...REGESMOHS (Registro Espanol de Cirugia de Mohs)	31777957	2020
41	Dermoscopic pitfall: Microcystic adnexal carcinoma mimicking basal cell carcinoma. ⁶²	Gupta V...Ramam M	31997790	2020
42	Microcystic Adnexal Carcinoma of the Face Treated With Definitive Chemoradiation: A Case Report and Review of the Literature. ⁶²	Kim DW...Tishler RB	32280832	2020
43	Solid Microcystic Adnexal Carcinoma on the Thigh: An Unusual Location. ⁶²	Diago A...Requena C	31436574	2020
44	Ln-γ 2 chain of laminin-332 is a useful marker in differentiating between benign and malignant sclerosing adnexal neoplasms. ⁶²	Koga K...Nabeshima K	31429981	2020
45	An atypical presentation of extensive centrofacial microcystic adnexal carcinoma responding to radiation: A case report and review of the literature. ⁶²	Hinther K...Asiniwasis RN	33062278	2020
46	Microcystic adnexal carcinoma: report of rare cases. ⁶²	Zhang L...Cao H	31912868	2020
47	Microcystic Adnexal Carcinoma: A Rare, Commonly Misdiagnosed Malignancy. ⁶²	Gerall CD...Hogan FS	31125069	2019
48	Approaches to Perineural, Lymphovascular, and Single-Cell Disease. ⁶²	Collins MK...Pugliano-Mauro M	31764297	2019
49	Microcystic Adnexal Carcinoma Originating in a Nevus Sebaceous: A Case Report of a 16-year-old Boy. ⁶²	Hashem R...Falk L	31386165	2019
50	Bilateral Facial Apocrine Fibrosing Hamartoma Mimicking Microcystic Adnexal Carcinoma. ⁶²	Llamas-Velasco M...Rutten A	31045870	2019

Sources

Genes for Malignant Syringoma

Genes related to Malignant Syringoma (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PHLDA1	Pleckstrin Homology Like Domain Family A Member 1	Protein Coding	7.07	DISEASES inferred ¹⁴
2	KRT15	Keratin 15	Protein Coding	6.8	DISEASES inferred ¹⁴
3	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.23	DISEASES inferred ¹⁴
4	PIP	Prolactin Induced Protein	Protein Coding	6.04	DISEASES inferred ¹⁴
5	PTGER4	Prostaglandin E Receptor 4	Protein Coding	5.98	DISEASES inferred ¹⁴
6	KRT5	Keratin 5	Protein Coding	5.94	DISEASES inferred ¹⁴
7	KRT7	Keratin 7	Protein Coding	5.9	DISEASES inferred ¹⁴
8	DOCK8	Dedicator Of Cytokinesis 8	Protein Coding	5.51	DISEASES inferred ¹⁴
9	KRT20	Keratin 20	Protein Coding	5.47	DISEASES inferred ¹⁴
10	KRT17	Keratin 17	Protein Coding	5.19	DISEASES inferred ¹⁴
11	KRT19	Keratin 19	Protein Coding	5.13	DISEASES inferred ¹⁴
12	CD34	CD34 Molecule	Protein Coding	4.83	DISEASES inferred ¹⁴

Sources

Variations for Malignant Syringoma

Cosmic variations for Malignant Syringoma:

⁸ (show top 50) (show all 1402)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM144653327	TP53	skin,face,carcinoma,NS	c.*131C>T	p.?	17:7670685-7670685	7
2	COSM112254631	TP53	skin,face,carcinoma,NS	c.586C>T	p.R196*	17:7674945-7674945	7
3	COSM143371865	TP53	skin,face,carcinoma,NS	c.469C>T	p.R157*	17:7674945-7674945	7
4	COSM93183824	TP53	skin,face,carcinoma,NS	c.680C>T	p.S227F	17:7674283-7674283	7
5	COSM143943797	TP53	skin,neck,carcinoma,NS	c.266G>A	p.R89Q	17:7674220-7674220	7
6	COSM121875437	TP53	skin,face,carcinoma,NS	c.178C>T	p.Q60*	17:7674957-7674957	7
7	COSM143388508	TP53	skin,face,carcinoma,NS	c.629G>C	p.R210T	17:7674217-7674217	7
8	COSM111758868	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	7
9	COSM142570304	TP53	skin,face,carcinoma,NS	c.715C>T	p.P239S	17:7673788-7673788	7
10	COSM142560384	TP53	skin,face,carcinoma,NS	c.616G>T	p.G206C	17:7674230-7674230	7
11	COSM142742951	TP53	skin,face,carcinoma,NS	c.315G>A	p.Q105=	17:7675180-7675180	7
12	COSM105639284	TP53	skin,face,carcinoma,NS	c.712T>A	p.C238S	17:7674251-7674251	7
13	COSM112253879	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	7
14	COSM121878773	TP53	skin,face,carcinoma,NS	c.241C>T	p.R81*	17:7674894-7674894	7
15	COSM111776406	TP53	skin,face,carcinoma,NS	c.993+1G>A	p.?	17:7673534-7673534	7
16	COSM142837551	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	7
17	COSM122742188	TP53	skin,face,carcinoma,NS	c.58C>T	p.P20S	17:7675158-7675158	7
18	COSM122735020	TP53	skin,face,carcinoma,NS	c.190C>T	p.R64*	17:7674945-7674945	7
19	COSM144028845	TP53	skin,face,carcinoma,NS	c.679T>A	p.C227S	17:7674251-7674251	7
20	COSM144021997	TP53	skin,face,carcinoma,NS	c.421C>T	p.P141S	17:7675158-7675158	7
21	COSM144015364	TP53	skin,face,carcinoma,NS	c.604C>T	p.R202*	17:7674894-7674894	7
22	COSM121877621	TP53	skin,face,carcinoma,NS	c.190C>T	p.R64*	17:7674945-7674945	7
23	COSM93201188	TP53	skin,face,carcinoma,NS	c.993+1G>A	p.?	17:7673534-7673534	7
24	COSM144658487	TP53	skin,face,carcinoma,NS	c.143C>A	p.P48Q	17:7676109-7676109	7
25	COSM142639459	TP53	skin,face,carcinoma,NS	c.597T>A	p.C199*	17:7674249-7674249	7
26	COSM105620390	TP53	skin,face,carcinoma,NS	c.733G>T	p.G245C	17:7674230-7674230	7
27	COSM144014436	TP53	skin,face,carcinoma,NS	c.553C>T	p.R185*	17:7674945-7674945	7
28	COSM112253194	TP53	skin,face,carcinoma,NS	c.833C>G	p.P278R	17:7673787-7673787	7
29	COSM112263720	TP53	skin,face,carcinoma,NS	c.832C>T	p.P278S	17:7673788-7673788	7
30	COSM122272676	TP53	skin,face,carcinoma,NS	c.190C>T	p.R64*	17:7674945-7674945	7
31	COSM93239210	TP53	skin,face,carcinoma,NS	c.706T>C	p.Y236H	17:7674257-7674257	7
32	COSM144651436	TP53	skin,face,carcinoma,NS	c.625C>T	p.R209W	17:7674221-7674221	7
33	COSM105620642	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	7
34	COSM144013959	TP53	skin,face,carcinoma,NS	c.502C>T	p.H168Y	17:7675077-7675077	7
35	COSM143949062	TP53	skin,face,carcinoma,NS	c.263A>C	p.N88T	17:7674223-7674223	7
36	COSM121876459	TP53	skin,face,carcinoma,NS	c.346C>T	p.R116W	17:7674221-7674221	7
37	COSM111775215	TP53	skin,face,carcinoma,NS	c.746G>C	p.R249T	17:7674217-7674217	7
38	COSM111765498	TP53	skin,face,carcinoma,NS	c.854A>T	p.E285V	17:7673766-7673766	7
39	COSM142838765	TP53	skin,face,carcinoma,NS	c.*131C>T	p.?	17:7670685-7670685	7
40	COSM93191278	TP53	skin,face,carcinoma,NS	c.517G>A	p.V173M	17:7675095-7675095	7
41	COSM144129318	TP53	skin,face,carcinoma,NS	c.229T>C	p.Y77H	17:7674257-7674257	7
42	COSM144088618	TP53	skin,face,carcinoma,NS	c.160C>T	p.R54*	17:7674894-7674894	7
43	COSM87910628	TP53	skin,face,carcinoma,NS	c.772G>A	p.E258K	17:7674191-7674191	7
44	COSM87898709	TP53	skin,face,carcinoma,NS	c.742C>T	p.R248W	17:7674221-7674221	7
45	COSM144691571	TP53	skin,face,carcinoma,NS	c.302C>T	p.T101I	17:7675193-7675193	7
46	COSM144013187	TP53	skin,face,carcinoma,NS	c.800C>G	p.P267R	17:7673787-7673787	7
47	COSM143156943	TP53	skin,face,carcinoma,NS	c.203C>T	p.S68F	17:7674283-7674283	7
48	COSM144324830	TP53	skin,face,carcinoma,NS	c.595T>A	p.C199S	17:7674251-7674251	7
49	COSM144662686	TP53	skin,face,carcinoma,NS	c.715C>T	p.P239S	17:7673788-7673788	7
50	COSM144650676	TP53	skin,face,carcinoma,NS	c.457C>T	p.Q153*	17:7674957-7674957	7

Sources

Expression for Malignant Syringoma

Search GEO for disease gene expression data for Malignant Syringoma.

Sources

Pathways for Malignant Syringoma

Pathways related to Malignant Syringoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	COPI-independent Golgi-to-ER retrograde traffic ⁶⁶ Show member pathways Cell cycle Spindle assembly and chromosome separation ²² Cytoskeleton remodeling Keratin filaments ²² Cytoskeleton remodeling Neurofilaments ²² HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand ⁶⁶	11.95	KRT7 KRT5 KRT19 KRT17
2	Cytoskeletal Signaling ³	11.84	KRT7 KRT5 KRT20 KRT19 KRT17
3	Keratinization ⁶⁶ Show member pathways Formation of the cornified envelope ⁶⁶	11.64	KRT7 KRT5 KRT20 KRT19 KRT17 KRT15

Sources

GO Terms for Malignant Syringoma

Cellular components related to Malignant Syringoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	keratin filament	GO:0045095	9.63	KRT7 KRT5 KRT17
2	intermediate filament	GO:0005882	9.36	KRT7 KRT5 KRT20 KRT19 KRT17 KRT15
3	cell periphery	GO:0071944	9.26	KRT19 KRT17 CD34

Biological processes related to Malignant Syringoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	keratinization	GO:0031424	9.63	KRT7 KRT5 KRT17
2	negative regulation of T cell apoptotic process	GO:0070233	9.56	PIP DOCK8
3	epithelial cell differentiation	GO:0030855	9.56	KRT20 KRT19 KRT17 KRT15
4	intermediate filament organization	GO:0045109	9.4	KRT7 KRT5 KRT20 KRT19 KRT17 KRT15

Molecular functions related to Malignant Syringoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	structural molecule activity	GO:0005198	9.35	KRT20 KRT19 KRT17 KRT15
2	structural constituent of cytoskeleton	GO:0005200	9.23	KRT5 KRT20 KRT19 KRT15

Sources

Sources for Malignant Syringoma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: MLG049 MIFTS: 42	Malignant Syringoma Categories: Cancer diseases, Eye diseases, Rare diseases, Reproductive diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables